Below are some common questions around whole genome sequencing and the potential of this testing for patients and their treatment plan.
Further information on WGS can be found here.
Whole genome sequencing (often shortened to WGS) is a type of genomic test that looks at the DNA in your brain tumour, using a sample taken during your operation (if you are able to have surgery). The tumour DNA is compared with DNA taken from a blood sample, to identify any changes (sometimes called mutations) in the tumour’s DNA sequence. WGS is the most comprehensive form of genomic testing that is currently available and looks at the entire genome. A genome is the complete set of DNA that makes up our bodies.
The results from WGS testing may be used for some or all of the following:
In summary, WGS testing gives your medical team more information about your tumour which could be (but not always) used to help them personalise your care.
The national genomic test directory outlines which tests are funded by the NHS in England and which patients are eligible to access these tests (1). According to the test directory in England, all adult patients with a neurological tumour can access WGS. Scotland, Wales and Northern Ireland have their own test directories, and the WGS service is not yet fully rolled out and funded in these countries.
As our Closing the Gap report describes in detail, the WGS service in England is relatively new, and hospitals are still establishing their processes in order to be able to deliver the test and report back on the results. Therefore, WGS testing is not easily available in all hospitals at present and test results may take some time.
Our report also found that while capacity is limited, the test can at times be prioritised for certain patient groups. You could therefore discuss with your oncologist or surgeon whether WGS is available, suitable for you and how long the test may take to report back.
The Tessa Jowell Brain Cancer Mission supports the increased adoption of WGS in the UK, so that in time, more patients may have the potential to benefit from personalised medicine.
No – to date, all NHS-approved brain tumour treatments can be accessed in every hospital without WGS testing, so you should not be worried that you will be missing out on standard treatments.
Contact us – We are working with a number of brain tumour charities and organisations in the UK to provide further information and advocate for the roll-out of this test.
The Genomics England website also has information on genomic testing and how patients can be involved in shaping the future of genomic testing.
Disclaimer: The information provided in this patient FAQ is intended for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this patient FAQ. In case of a medical emergency dial emergency services immediately. The information in this patient FAQ is provided “as is” without any representations or warranties, express or implied. We do not guarantee the accuracy, completeness, or usefulness of the information provided, and we disclaim all liability for any actions taken based on this patient FAQ.
